Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.31 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.31 |
| ▸ | RBP4 | P02753 | 1/20 | 0.31 |
| ▸ | PDE1A | P54750 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20186695 | 0.88 | ABCB1 (0.38) | ABCB1ABCG2MTNR1BHDAC6HDAC1 | |
| SCHEMBL20186810 | 0.88 | AKR1B10 (0.33) | MTNR1BKDM4EAKR1B10AKR1B1 | |
| SCHEMBL20186663 | 0.84 | ABCG2 (0.41) | ABCB1ABCG2 | |
| SCHEMBL20186640 | 0.76 | NOD1 (0.36) | — | |
| SCHEMBL20186802 | 0.74 | HSD17B10 (0.31) | KDM4E | |
| SCHEMBL20204833 | 0.73 | MEN1 (0.52) | ABCB1ABCG2KDM4E | |
| SCHEMBL18201331 | 0.73 | MEN1 (0.52) | ABCB1ABCG2KDM4E | |
| SCHEMBL20200994 | 0.68 | SLC6A4 (0.42) | ABCB1ABCG2KDM4E | |
| SCHEMBL20186647 | 0.68 | HTR6 (0.37) | KDM4E | |
| SCHEMBL20186744 | 0.62 | HTR2A (0.39) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10253024-B2 | Polycyclic indoline and indolenine compounds | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2019-04-09 | — | — | US | disclosed |
| US-20180148442-A1 | Polycyclic Indoline and Indolenine Compounds | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2018-05-31 | — | — | US | disclosed |
| US-20180148442-A1 | Polycyclic Indoline and Indolenine Compounds | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2018-05-31 | — | — | US | disclosed |
| WO-2016176634-A1 | POLYCYCLIC INDOLINE AND INDOLENINE COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2016-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10253024-B2 | Polycyclic indoline and indolenine compounds | IDO1, IDO2, INMT | ABCB1 736/4885ABCG2 1597/4885MTNR1B 57/4885 |
| US-20180148442-A1 | Polycyclic Indoline and Indolenine Compounds | IDO1, IDO2, INMT | ABCB1 736/4885ABCG2 1597/4885MTNR1B 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.